2022-06-10 | NDAQ:GTBP | Press Release | GT Biopharma Inc. :

(2022-06-10 | NDAQ:GTBP) GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Related Keywords

United States , Brisbane , Queensland , Australia , American , Biopharma Closecurlyquote , Corey Davis , Jeff Miller Closecurlyquote , Gregory Berk , Globe Newswire Gt Biopharma Inc , European Hematology Association , Company Closecurlydoublequote , Nasdaq , Exchange Commission , Company Closecurlyquote , Congress Poster Details , University Of Minnesota , Gt Biopharma Inc , American Cancer Society , Tri Specific Killer Engager Drives Robust , Function Againstb Cell Malignancies , Chief Medical Officer , Poster Details , Relations Contacts , Healthcare 37 , Biotechnology 121 , Diagnostics Research 128 , Usa 8 , Biotechnology 70569 ,